Scholarlink

<p>Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson’s disease (PD). Here we focused on mGlu3, a receptor subtype involved in synaptic regulation and neuroinflammation. mGlu3<sup>−/−</sup> mice showed an enhanced nigro-striatal damage and microglial activation in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Expression of genes encoding anti-inflammatory proteins and neuroprotective factors was reduced in the striatum of MPTP-treated mGlu3<sup>−/−</sup> mice. We also examined polymorphic variants of <i>GRM3</i> (the mGlu3 receptor encoding gene) in 723 PD patients and 826 healthy controls. Two <i>GRM3</i> haplotypes were associated with PD, and gene variants correlated with motor and non-motor signs. Interestingly, PD patients carrying each of the two haplotypes showed an impaired cortical plasticity in the paired associated stimulation paradigm of magnetic transcranial stimulation. These findings suggest that mGlu3 receptors are neuroprotective in mouse models of parkinsonism and shape mechanisms of cortical plasticity in PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical and clinical study on type 3 metabotropic glutamate receptors in Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月4日

查看全文
  • Luisa Di Menna,
  • Marika Alborghetti,
  • Maria Ilenia De Bartolo,
  • Marina Borro,
  • Giovanna Gentile,
  • Manuela Zinni,
  • Matteo Bologna,
  • Carolina Cutrona,
  • Giovanna D’Errico,
  • Tiziana Imbriglio,
  • Domenico Bucci,
  • Sara Merlo,
  • Roxana Paula Ginerete,
  • Rosamaria Orlando,
  • Federica Carrillo,
  • Giorgio Fortunato,
  • Milena Cannella,
  • Maria Angela Sortino,
  • Julien Pansiot,
  • Olivier Baud,
  • Ferdinando Nicoletti,
  • Valeria Bruno,
  • Maurizio Simmaco,
  • Francesco Ernesto Pontieri,
  • Edoardo Bianchini,
  • Domiziana Rinaldi,
  • Amalia de Curtis,
  • Giovanni De Gaetano,
  • Licia Iacoviello,
  • Teresa Esposito,
  • Alfredo Berardelli,
  • Giuseppe Battaglia

摘要

Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson’s disease (PD). Here we focused on mGlu3, a receptor subtype involved in synaptic regulation and neuroinflammation. mGlu3−/− mice showed an enhanced nigro-striatal damage and microglial activation in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Expression of genes encoding anti-inflammatory proteins and neuroprotective factors was reduced in the striatum of MPTP-treated mGlu3−/− mice. We also examined polymorphic variants of GRM3 (the mGlu3 receptor encoding gene) in 723 PD patients and 826 healthy controls. Two GRM3 haplotypes were associated with PD, and gene variants correlated with motor and non-motor signs. Interestingly, PD patients carrying each of the two haplotypes showed an impaired cortical plasticity in the paired associated stimulation paradigm of magnetic transcranial stimulation. These findings suggest that mGlu3 receptors are neuroprotective in mouse models of parkinsonism and shape mechanisms of cortical plasticity in PD.